Liquid Biopsy Market over $0.4 Bn in 2017

Wednesday 1 March 2017, Amsterdam

This new report, now available on ASDReports, the Global Liquid Biopsy Market Forecast 2017-2027: Analysis of the Liquid Biopsy Market by Sample Type, Biomarker, Application and End User indicates that the global liquid biopsy market will see over $0.4bn in revenue in 2017.

The lead analyst of the report said:

“Liquid Biopsies are one of the most exciting sectors of the diagnostics market over the next decade, as increasing acceptance of liquid biopsy methods, coupled with the increase in patient comfort, using a minimally invasive technique, and the increasing aging population, with its associated increase in cancer rates, will all combine to provide perfect circumstances for growth in the market. Although the market is currently small, there will be much growth over the forecast period, leading to opportunities that can be exploited.”

The 204-page report contains 190 tables, charts and graphs that add visual analysis in order to explain developing trends within the liquid biopsy market. The key player provides revenue forecasts for the period 2017-2027 for the leading liquid biopsy submarkets with 4 segmentations of the market, namely the liquid biopsy market by sample type (blood, urine, other), biomarker type (CTC, ctDNA, Exosomes), application (Lung Cancer, Gastrointestinal Cancer, Breast Cancer, Colorectal Cancer, Leukaemia, Prostate Cancer, Other cancers) and end user (Hospitals, Academic Institutes, Diagnostic Laboratories, Cancer Research Centres).

The 204-page report offers market forecasts and analysis for 5 leading regional and 19 national markets, as well as the rest of Europe, rest of Latin America, Rest of APAC and Rest of MEA markets. In addition, the report contains a dedicated leading companies’ chapter covering more than 8 companies leading the field in liquid biopsy technology.